Insight combines EEG with automated neurocognitive tests and computes biosignatures referenced to our extensive normative database.
Provides researchers with individual participant reports.
These analytics assist in differentiating disease types, quantifying severity, tracking progression and assessing intervention efficacy.
Insight biomarkers include
Neurodegenerative
Psychiatric
Research
Insight is
Imaging Modalities
HEALTHY AGING
NEURODEGENERATION
Healthy aging can be differentiated from neurodegenerative decline
Participant 1 – Healthy
Participant 2 – Alzheimer’s
Insight is a fully mobile wireless device designed for use in any setting with rapid setup. New technicians can be trained and certified in a 4-hour session on-site.
64-year-old man – longitudinal study
Dx: amnestic MCI
Year 1 Participant scored 29 on MMSE
Year 2 Participant scored 25 on MMSE
MMSE score of 25 or higher is considered Normal
Although Participant’s Year 2 MMSE indicates Normal, his Insight biosignature clearly shows he has moved from healthy to MCI. This participant should be monitoring his health and may be a candidate for newly available treatment.
